Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|June 2, 2017
Phenomenex Opens New Manufacturing Facility
Author(s)Pharmaceutical Technology Editors
Phenomenex opened a new manufacturing and development facility in CA for the company’s gas chromatography columns.
Advertisement
On May 30, 2017, Phenomenex announced the opening of a new manufacturing and development facility dedicated to the company’s gas chromatography columns, marketed under the Zebron brand name. The 15,000-ft2 facility is located in El Dorado Hills, CA, a suburb of Sacramento. The new facility includes organic synthesis, R&D, and analytical labs. The new location supports twice the production capacity and will improve Phenomenex’s logistics and delivery speeds. In a
Source:
Advertisement
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
AI Formulation: Regulators Want Data
4
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
5